Elanco Animal Health reported third quarter 2026 results that exceeded expectations across top and bottom-line metrics, driven by strong uptake of new products and accelerated pricing power. The company reached a key debt reduction milestone, achieving a net leverage ratio of 2.9x ahead of schedule, and raised its full-year 2026 guidance.
Key Highlights
- Total revenue reached $1.265 billion, an 11% reported increase year-over-year, outperforming the $1.21 billion estimate on 9% organic constant currency growth.
- Adjusted EPS of $0.27 beat the $0.20 consensus, supported by a 300 basis point expansion in adjusted gross margin to 56.1% due to favorable product mix and pricing.
- U.S. Pet Health revenue increased 13% as Credelio Quattro became the company's largest U.S. branded product, surpassing Seresto in sales volume.
- Full-year 2026 adjusted EPS guidance was raised to a range of $1.17 to $1.20, representing 26% year-over-year growth at the midpoint.